DNG 10 - Prospective dengue sero-prevalence Study in 5 to 10 Year-old children in India – A community based descriptive cross sectional study

Principal investigator:
Dr. Ganesh Oruganti, Director Public Health, SHARE INDIA.

Co- Investigators:
Dr. Enakshi Ganguly, Associate Professor,Department of Community Medicine, MediCiti Institute of Medical Sciences
Dr. Jammy Guru Rajesh, Tutor, Department of Community Medicine, MediCiti Institute of Medical Sciences.

Amount of funding: € 16,134 (Rs. 11.30 Lakhs)

Source of funding: Sanofi Pasteur, France.

This study was conducted geographically distinct sites across India and SHARE India implemented this study in 2 sites. to determine the prevalence of specific antibodies (immunoglobulin G, IgG) against Dengue in healthy 5 to 10 year-old children in India under the sponsorship of Sanofi Pasteur. This study was conducted in 8 Overall, Dengue IgG prevalence in the SHARE INDIA implementation sites was 58%. The proportion of seropositive subjects did not differ according to sex but differed according to age. Dengue IgG prevalence was higher in 8-10 year th old than in 5-7 year-old subjects. This study has been presented in the 10 Joint Annual Conference of ISMOCD and IAE, October 10–12, 2014, Goa, India.

DNG 09 - Prospective, multi-center, community-based incidence study of symptomatic dengue in India

Principal investigator:
Dr. Ganesh Oruganti, Director Public Health, SHARE INDIA.

Co- Investigator:
Dr. Jammy Guru Rajesh, Tutor, Department of Community Medicine, MediCiti Institute of Medical Sciences.
Dr. Enakshi Ganguly, Associate Professor, Department of Community Medicine, MediCiti Institute of Medical Sciences.

Amount of funding: Rs. 1.00 Crore (approximately)

Source of funding: Sanofi Pasteur, France.

This study is proposed to be conducted in 4 sites in India, of which SHARE INDIA will implement it in one site under the sponsorship of Sanofi Pasteur. This is a population-based prospective study to estimate the population-based incidence of symptomatic laboratory-confirmed dengue infection in the catchment population of each study site. Necessary approvals for this study are in progress.